Profile: Alliance Pharma PLC (ALAPH.L)

ALAPH.L on London Stock Exchange

34.50GBp
19 Dec 2014
Price Change (% chg)

-0.12p (-0.36%)
Prev Close
34.62p
Open
34.62p
Day's High
--
Day's Low
--
Volume
138,072
Avg. Vol
130,951
52-wk High
41.00p
52-wk Low
30.00p

Search Stocks
Alliance Pharma plc is a speciality pharmaceutical company. The principal activity of the Company is the acquisition, marketing and distribution of pharmaceutical products. The Company promotes products in two areas of specialization, Dermatology and Secondary Care. Its dermatology product portfolio includes Acnisal, Hydromol, Pentrax, Alphaderm, Isotretinoin, Permitabs, Aquadrate, Meted, Quinoderm, Atarax, Naseptin, Timodine, Dermamist and Occlusal. The Company’s product portfolio in the secondary care includes Absorbagel, ImmuCyst, Naturcare, Clearway, La Vera, SkinSafe, Deogel, Lift, Ultracleanse, Gelclair and Lift plus. In December 2013, Alliance Pharma plc announced that its wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired all the United Kingdom and Republic of Ireland (ROI) rights to Lypsyl from Novartis AG.

Company Address

Alliance Pharma PLC

Avonbridge House
Bath Road
CHIPPENHAM     SN15 2BB
P: +441249.466966
F: +441249.466977

Search Stocks